Edition:
United States

Profile: Derma Sciences Inc (DSCI.OQ)

DSCI.OQ on NASDAQ Stock Exchange Capital Market

4.50USD
2 Dec 2016
Change (% chg)

$-0.25 (-5.26%)
Prev Close
$4.75
Open
$4.70
Day's High
$4.70
Day's Low
$4.50
Volume
1,767
Avg. Vol
9,090
52-wk High
$5.74
52-wk Low
$2.85

Derma Sciences, Inc. (Derma Sciences), incorporated on November 9, 1990, is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. Advanced and traditional wound care products are marketed globally to acute care, extended care, home healthcare, wound and burn care clinics and physician offices.

Advanced Wound Care

The Company's advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. MEDIHONEY offers a line of dressings, consisting of Active Leptospermum Honey. MEDIHONEY dressings manage non-chronic and hard-to-heal wounds, including chronic ulcers, burns and post-operative wounds. TCC-EZ is an off-loading system for patients with diabetic foot ulcers. AMNIOEXCEL is an amniotic extracellular membrane product that is a sterile, room-temperature stable, re-absorbable tissue allograft derived from human amnion, providing a natural scaffold for tissue repair, reconstruction and replacement. AMNIOMATRIX is a cryopreserved liquid allograft derived from human placenta tissue used as a wound covering in the treatment of localized tissue defects. The addressable skin substitute market includes traumatic injuries, burns, surgical wounds, complex chronic and acute wounds, and other soft-tissue defects. XTRASORB provides a line of dressings that utilizes super-absorbent polymer technologies. XTRASORB dressings convert fluid within the dressings to a gel, thus locking the exudates into the dressings. BIOGUARD is a line of primary and secondary dressings containing an active antimicrobial compound. This compound, a cationic biocide, is intrinsically bound to the dressing through a process that results in the inability for the compound to separate from the dressing. These dressings prevent hospital or community acquired infections through wound sites, especially for burns. The Company's other advanced wound care products include ALGICELL AG, a antimicrobial dressing with ionic silver as its active ingredient, and a range of moist, occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers and DERMAGRAN products.

Traditional Wound Care

The Company's traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets. It offers a line of branded and private-label adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. The Company also offers private-label wound care products for the United States and international healthcare companies. It provides a line of wound closure strips, nasal tube fasteners and a range of catheter fasteners for the medical markets. In addition, the Company offers a line of general purpose and specialized skin care products for the institutional medical market.

Company Address

Derma Sciences Inc

214 Carnegie Ctr Ste 300
PRINCETON   NJ   08540-6237
P: +1609.5144744

Company Web Links